Controversy in Diagnosis and Management of the Metabolic Syndrome

Medical Clinics of North America

Volumn 91, Issue 6, 2007, Pages 1041-1061

  Brietzke, Stephen A ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; C REACTIVE PROTEIN; GEMFIBROZIL; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; STATINE DERIVATIVE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIET THERAPY; DRUG DOSE TITRATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; KINESIOTHERAPY; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

CORONARY DISEASE; DIABETES MELLITUS; DIAGNOSIS, DIFFERENTIAL; EXERCISE THERAPY; HUMANS; METABOLIC SYNDROME X; PRACTICE GUIDELINES AS TOPIC;

EID: 35549011412     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2007.06.005     Document Type: Review

References (93)

1. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. [review][71 refs]. Diabetes 37 12 (1988) 1595-1607
2. Kaski J.C., and Elliott P.M. Angina pectoris and normal coronary arteriograms: clinical presentation and hemodynamic characteristics. [review][48 refs]. Am J Cardiol 76 13 (1995) 35D-42D
3. Ford E.S., Giles W.H., and Mokdad A.H. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27 (2004) 2444-2449
4. Ford E.S. Rarer than a blue moon: the use of a diagnostic code for the metabolic syndrome in the U.S. Diabetes Care 28 (2005) 1808-1809
5. Davidson M.B. Is treatment of insulin resistance beneficial independent of glycemia?. Diabetes Care 26 (2003) 3184-3186
6. Kahn R., Buse J., Ferrannini E., et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
7. Grundy S.M. Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscler Thromb Vasc Biol 25 (2005) 2243-2244
8. Blaha M., and Elasy T.A. Clinical use of the metabolic syndrome: why the confusion?. Clin Diabetes 24 (2006) 125-131
9. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. [see comment][review][14 refs]. Circulation 109 3 (2004) 433-438
10. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
11. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. [see comment]. Diabet Med 15 7 (1998) 539-553
12. Einhorn D., Reaven G.M., Cobin R.H., et al. American College of Endocrinology position statement on the insulin resistance syndrome. [review][0 refs]. Endocr Pract 9 3 (2003) 237-252
13. Alberti K.G., Zimmet P., and Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. [review][80 refs]. Diabet Med 23 5 (2006) 469-480
14. Abbasi F., Brown B.W., Lamendola C., et al. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 40 (2002) 937-943
15. Facchini F.S., Hua N., Abbasi F., et al. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 86 (2001) 3574-3578
16. Wilson P.W.F., D'Agostino R.B., Parise H., et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112 (2005) 3066-3072
17. Sundstrom J., Riserus U., Byberg L., et al. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 332 (2006) 878-882
18. Wannamethee S.G.P., Shaper A.G.F., Lennon L.M., et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. [article]. Arch Intern Med 165 (2005) 2644-2650
19. Najarian R.M.M., Sullivan L.M.P., Kannel W.B.M., et al. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. [article]. Arch Intern Med 166 (2006) 106-111
20. Lorenzo C., Williams K., Hunt K.J., et al. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30 (2007) 8-13
21. Fujioka S., Matsuzawa Y., Tokunaga K., et al. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36 (1987) 54-59
22. Ahima R.S. Adipose tissue as an endocrine organ. Obesity 14 (2006) 242S-249S
23. Pittas A.G., Joseph N.A., and Greenberg A.S. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 89 (2004) 447-452
24. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
25. Gable D.R., Hurel S.J., and Humphries S.E. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 188 (2006) 231-244
26. Fasshauer M., Kralisch S., Klier M., et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 301 (2003) 1045-1050
27. Tataranni P.A., and Ortega E. A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes?. Diabetes 54 (2005) 917-927
28. Koh K.K., Han S.H., and Quon M.J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. [review][84 refs]. J Am Coll Cardiol 46 11 (2005) 1978-1985
29. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-{kappa}B signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
30. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. [review][57 refs]. Nat Clin Pract Cardiovasc Med 3 1 (2006) 35-42
31. Chen H., Montagnani M., Funahashi T., et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278 (2003) 45021-45026
32. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
33. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
34. Iwashima Y., Katsuya T., Ishikawa K., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43 (2004) 1318-1323
35. Adamczak M., Wiecek A., Funahashi T., et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 16 (2003) 72-75
36. Choi K.M., Lee J., Lee K.W., et al. The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors. Eur J Endocrinol 150 (2004) 715-718
37. Higashiura K., Ura N., Ohata J., et al. Correlations of adiponectin level with insulin resistance and atherosclerosis in Japanese male populations. Clin Endocrinol 61 (2004) 753-759
38. Tschritter O., Fritsche A., Thamer C., et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52 (2003) 239-243
39. Lindsay R.S., Funahashi T., Hanson R.L., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002) 57-58
40. Daimon M., Oizumi T., Saitoh T., et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata Study. Diabetes Care 26 (2003) 2015-2020
41. Hulthe J., Hulten L.M., and Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 52 (2003) 1612-1614
42. Matsubara M., Maruoka S., and Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87 (2002) 2764-2769
43. Pischon T.M., Girman C.J.D., Hotamisligil G.S.M.P., et al. Plasma adiponectin levels and risk of myocardial infarction in men. [article]. JAMA 291 (2004) 1730-1737
44. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
45. Zoccali C., Mallamaci F., Tripepi G., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13 (2002) 134-141
46. Schulze M.B., Shai I., Rimm E.B., et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54 (2005) 534-539
47. Okamoto Y., Kihara S., Funahashi T., et al. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci 110 (2006) 267-278
48. Esposito K.M., Pontillo A.M., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. [article]. JAMA 289 (2003) 1799-1804
49. Yang W.S., Lee W.J., Funahashi T., et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86 (2001) 3815-3819
50. Duncan B.B., Schmidt M.I., Pankow J.S., et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52 (2003) 1799-1805
51. Hu F.B., Meigs J.B., Li T.Y., et al. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53 (2004) 693-700
52. Torres J.L., and Ridker P.M. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. [Miscellaneous article]. Curr Opin Cardiol 18 (2003) 471-478
53. Ridker P.M., Rifai N., Stampfer M.J., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
54. Ouchi N., Kihara S., Funahashi T., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107 (2003) 671-674
55. Dandona P., Weinstock R., Thusu K., et al. Tumor necrosis factor-{alpha} in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83 (1998) 2907-2910
56. Lihn A.S., Ostergard T., Nyholm B., et al. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab 284 (2003) E443-E448
57. Stefan N., Vozarova B., Funahashi T., et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51 (2002) 1884-1888
58. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
59. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
60. Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care 20 (1997) 537-544
61. DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
62. Whelton S.P., Chin A., Xin X., et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. [see comment][summary for patients in Ann Intern Med. 2002 Apr 2;136(7):I16; PMID: 11926806]. Ann Intern Med 136 7 (2002) 493-503
63. Kelley G.A., Kelley K.S., and Tran Z.V. Walking and resting blood pressure in adults: a meta-analysis. Prev Med 33 2 Pt 1 (2001) 120-127
64. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. [see comment]. Hypertension 42 6 (2003) 1206-1252
65. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
66. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
67. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. [see comment]. Lancet 361 9364 (2003) 1149-1158
68. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study: implications for treatment. [see comment]. Circulation 85 1 (1992) 37-45
69. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 6 (1999) 410-418
70. Dormandy J.A., Charbonnel B., Eckland D.J.A., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
71. Freemantle N. How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?. [Miscellaneous]. BMJ 331 (2005) 836-838
72. Fonseca V., Jawa A., and Asnani S. The PROactive Study: the glass is half full. J Clin Endocrinol Metab 91 (2006) 25-27
73. Rizza R., Henry R., and Kahn R. Commentary on the results and clinical implications of the PROactive study. Diabetes Care 28 (2005) 2965-2967
74. Gress T.W., Nieto F.J., Shahar E., et al. The atherosclerosis risk in communities study: hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 342 (2000) 905-912
75. Gurwitz J.H., Bohn R.L., Glynn R.J., et al. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med 118 (1993) 273-278
76. Savage P.J., Pressel S.L., Curb J.D., et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the systolic hypertension in the elderly program. Arch Intern Med 158 (1998) 741-751
77. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [see comment][erratum appears in JAMA 2003 Jan 8;289(2):178]. JAMA 288 23 (2002) 2981-2997
78. Kurtz T.W. New treatment strategies for patients with hypertension and insulin resistance. Am J Med 119 (2006) S24-S30
79. Shadid S., and Jensen M.D. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 26 (2003) 3148-3152
80. Tack C.J., Smits P., Demacker P.N., et al. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 21 (1998) 796-799
81. Winkler K., Konrad T., Fullert S., et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 26 (2003) 2588-2594
82. Raji A., Seely E.W., Bekins S.A., et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 26 (2003) 172-178
83. Hirose H., Kawai T., Yamamoto Y., et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51 (2002) 314-317
84. Maeda N., Takahashi M., Funahashi T., et al. PPAR{gamma} ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
85. Yu J.G., Javorschi S., Hevener A.L., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
86. Ridker P.M., Hennekens C.H., Roitman-Johnson B., et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351 (1998) 88-92
87. Ito H., Ohshima A., Inoue M., et al. Weight reduction decreases soluble cellular adhesion molecules in obese women. Clin Exp Pharmacol Physiol 29 (2002) 399-404
88. Koh K.K., Son J.W., Ahn J.Y., et al. Vascular effects of diet and statin in hypercholesterolemic patients. Int J Cardiol 95 (2004) 185-191
89. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 23 (2002) 482-487
90. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland coronary prevention study. Circulation 103 (2001) 357-362
91. Koh K.K., Han S.H., Quon M.J., et al. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28 (2005) 1419-1424
92. Wassmann S., Hilgers S., Laufs U., et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 22 (2002) 1208-1212
93. Koh K.K., Han S.H., Chung W.J., et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 93 (2004) 1432-1435